prevent
infecti
diseas
via
prophylact
immun
mainstay
global
public
health
effort
vaccin
design
would
facilit
better
understand
type
durabl
immun
respons
gener
differ
vaccin
vector
report
result
compar
immunogen
trial
six
differ
vaccin
vector
express
insert
antigen
cowpox
viru
vector
test
recombin
adenoviru
immunogen
induc
highest
titer
antibodi
confer
protect
subleth
vaccinia
viru
challeng
mice
singl
immun
test
select
heterolog
primeboost
combin
identifi
recombin
vesicular
stomat
viru
rvsv
recombin
venezuelan
equin
enceph
viru
replicon
vrp
synergist
regimen
compar
data
present
critic
effort
gener
protect
vaccin
emerg
infecti
diseas
well
biothreat
agent
immun
smallpox
polio
childhood
diseas
diptheria
whoop
cough
lead
erad
control
diseas
global
societi
face
new
array
emerg
reemerg
pathogen
sar
west
nile
viru
avian
influenza
highli
effect
vaccin
urgent
need
addit
threat
bioterror
via
deliber
reintroduct
pathogen
smallpox
variola
increas
concern
difficult
predict
type
new
pathogen
may
emerg
thu
develop
arsen
rapidli
mobiliz
vaccin
platform
highli
desir
ideal
creation
panel
vaccin
vector
would
allow
vaccin
product
util
common
platform
technolog
date
method
vaccin
design
hamper
lack
headtohead
comparison
avail
vaccin
vector
goal
studi
compar
six
differ
vaccin
vector
singl
primeboost
immunogen
trial
rel
immunogen
individu
vector
well
synergist
primeboost
combin
could
determin
human
vaccin
induc
humor
respons
vaccin
antigen
vaccine
rel
import
cellular
humor
respons
induct
mainten
protect
area
consider
controversi
like
differ
pathogen
despit
passiv
transfer
studi
shown
vaccineinduc
antibodi
suffici
confer
protect
viral
infect
measl
mump
varicella
zoster
human
similarli
induct
protect
antibodi
shown
correl
protect
anim
model
emerg
infect
plagu
poxvirus
sar
reason
chose
compar
vaccin
vector
express
antigen
known
induc
strong
humor
respons
import
biodefens
vector
studi
express
secret
form
poxviru
antigen
express
outer
membran
extracellular
envelop
infecti
virion
eev
target
host
neutral
antibodi
thought
involv
long
rang
dissemin
poxviru
virion
within
infect
host
highli
conserv
among
mammalian
poxviru
subspeci
induc
measur
cell
respons
mice
express
plasmid
dna
recombin
protein
nonrepl
recombin
adenoviru
highli
attenu
replic
compet
vesicular
stomat
viru
rvsv
venezuelan
enceph
viru
replicon
particl
veevrp
mycobacterium
smegmati
smeg
vector
wherea
recombin
adenoviru
immunogen
prime
vector
recombin
veevrp
prime
vsv
boost
optimum
heterolog
primeboost
induct
protect
antibodi
plasmid
dnaa
codonoptim
encod
amino
acid
ectodomain
cowpox
viru
cpxv
correspond
vaccinia
gener
convert
amino
acid
sequenc
cpxv
nucleotid
accord
human
codon
usag
highli
express
human
housekeep
gene
describ
codonoptim
cpxv
gene
synthes
de
novo
blue
heron
biotechnolog
bothel
wa
subclon
express
plasmid
pcmvr
gener
provid
dr
gari
nabel
nation
institut
healthvaccin
research
center
plasmid
dna
purifi
use
standard
method
endotoxin
free
suitabl
human
immun
forward
primer
revers
primer
use
pcr
amplifi
ectodomain
amino
acid
protein
cpxv
addit
nhei
kpni
restrict
endonucleas
site
well
ctermin
amplifi
fragment
clone
invitrogen
human
cell
transfect
express
construct
recombin
protein
purifi
nickel
column
cultur
supernat
recombin
adenovirusth
ectodomain
subclon
adaptor
plasmid
padapt
nonrepl
vector
produc
transfect
complement
cell
structur
cosmid
pweadafliiritr
lipofectamin
invitrogen
flask
cell
passag
flask
hr
maintain
viru
cytopath
effect
observ
vector
plaquepurifi
analyz
transgen
express
amplifi
triplelay
flask
purifi
doubl
cscl
gradient
ultracentrifug
dialyz
pb
contain
sucros
purifi
rad
vector
store
viru
particl
vp
titer
determin
spectrophotometri
specif
infect
assess
plaqu
form
unit
pfu
assay
dose
optim
test
rang
dose
vp
vp
order
find
dose
induc
highest
titer
ab
ab
detect
mice
receiv
vp
increas
accord
dose
dose
rang
fold
increas
titer
everi
log
differ
dose
titer
significantli
differ
mice
receiv
vs
vp
venezuelan
equin
enceph
repliconsveevrp
product
describ
previous
briefli
code
region
ectodomain
codon
optim
correspond
vaccinia
pcr
amplifi
plasmid
dna
use
primer
forward
atcgat
ggatcc
tta
revers
insert
vee
replicon
plasmid
next
encod
vee
nonstructur
protein
encapsid
signal
transgen
downstream
promot
two
helper
plasmid
encod
vee
capsid
vee
glycoprotein
linear
transcrib
use
mmessag
vitro
transcript
kit
ambion
attenu
glycoprotein
use
packag
vrp
transcript
electropor
bhk
cell
vrp
recov
cultur
supernat
purifi
ultracentrifug
sucros
cushion
concentr
vrp
resuspend
pb
store
dose
optim
test
rang
dose
pfu
pfu
order
find
dose
induc
highest
titer
ab
ab
detect
immun
mice
increas
accord
dose
fold
increas
titer
everi
log
differ
dose
obtain
plasmid
could
use
recov
rvsv
express
first
posit
vsv
genom
bp
dna
fragment
encod
ectodomain
amplifi
pcmvr
use
forward
primer
cctgcagctcgagaccatgaagaccatctccgtggtg
revers
primer
ctgcgacgtgctagcttagtggtaggtggcctccag
forward
primer
introduc
underlin
xhoi
site
upstream
code
sequenc
revers
insert
nhei
site
downstream
pcr
product
digest
xhoi
nhei
purifi
ligat
vector
digest
enzym
gener
pvsv
gener
provid
wyeth
pharmaceut
encod
scrambl
vsv
genom
yield
highli
attenu
rvsv
plasmid
recov
transform
escherichia
coli
invitrogen
purifi
use
plasmid
maxiprep
kit
qiagen
insert
sequenc
verifi
duke
sequenc
facil
recombin
viru
recov
plasmid
describ
previous
briefli
cell
grown
confluenc
infect
multipl
infect
moi
vaccinia
viru
express
rna
polymeras
obtain
nih
aid
reagent
repositori
one
hour
infect
cell
transfect
g
along
pbsn
pbsp
pbsl
pbsg
h
cell
supernat
passag
onto
cell
filter
millipor
medium
contain
viru
collect
hr
cytopath
effect
seen
virus
grown
individu
plaqu
use
prepar
stock
grown
cell
store
dose
optim
test
rang
dose
pfu
pfu
order
find
dose
induc
highest
titer
ab
ab
detect
immun
mice
increas
accord
dose
fold
increas
titer
everi
log
differ
dose
modifi
vaccinia
ankaramva
origin
provid
b
moss
nation
institut
health
grown
chicken
embryo
fibroblast
cell
line
atcc
immun
studi
mva
purifi
infect
cell
lysat
centrifug
sucros
cushion
prior
resuspens
pb
filtrat
viru
infect
determin
plaqu
assay
fibroblast
mycobacterium
smegmat
smegmati
mc
use
gener
recombin
smegmati
smegmati
cultur
grown
middlebrook
broth
difco
contain
albumindextros
salin
ad
tween
gener
recombin
smegmati
smegmati
mc
prepar
glycerol
transform
plasmid
electropor
gene
pulsar
biorad
set
kv
puls
control
resist
set
transform
smegmati
organ
select
middlebrook
difco
spark
md
agar
plate
supplement
ad
contain
either
kanamycin
monitor
express
individu
coloni
recombin
smegmati
grown
middlebrook
broth
presenc
kanamycin
harvest
centrifug
rins
steril
phosphatebuff
salin
mycobacteri
cell
lyse
use
modifi
extract
buffer
glass
bead
sigma
cell
lysat
clear
centrifug
lysat
recombin
smegmati
fraction
sodium
dodecyl
sulfatepolyacrylamid
gel
electrophoresi
blot
onto
nitrocellulos
filter
schleicher
schuell
germani
dose
optim
test
rang
dose
pfu
cfu
order
find
dose
induc
highest
titer
ab
ab
detect
mice
immun
cfu
titer
increas
accord
dose
fold
increas
titer
everi
log
differ
dose
mice
immunizationstenweekold
femal
mice
purchas
jackson
laboratori
hous
least
week
experi
initi
mice
hous
microisol
cage
biosafeti
level
anim
facil
vaccin
stock
dilut
appropri
titer
steril
immedi
prior
immun
intramuscular
vaccin
mice
receiv
singl
inject
right
quadricep
intranas
immun
mice
anesthet
use
isofluoran
vaporis
inocul
appropri
vaccin
per
nostril
institut
anim
care
use
committe
duke
univers
approv
anim
experi
vaccin
dose
amount
intramuscular
intranas
immun
dose
vaccin
vector
plasmid
dna
protein
administ
oligo
cpg
adjuv
iu
cfu
smegmati
vp
pfu
rvsv
pfu
mva
mock
immun
mice
receiv
steril
diluent
verif
express
verifi
vaccin
vector
via
western
blot
briefli
sampl
prepar
appropri
vector
resolv
sdspage
attempt
made
equal
protein
load
dispar
sampl
ie
dna
vrp
gel
transfer
nitrocellulos
blot
polyclon
rabbit
serum
rabbit
immun
protein
band
visual
use
western
blue
stain
promega
elisa
bind
antibodyimmulon
ii
elisa
plate
well
polystyren
fisher
coat
purifi
ng
per
well
bicarbon
buffer
overnight
well
wash
block
superblock
normal
goat
serum
whey
pbstween
incub
dilut
sera
antibodi
detect
alkalinephosphatas
conjug
goat
antimous
ig
antibodi
reactiv
detect
ad
pnpp
substrat
phosphat
sigma
direct
manufactur
incub
minut
read
ab
serum
ig
endpoint
titer
report
reciproc
highest
dilut
gave
absorb
greater
background
background
absorb
preimmun
serum
dilut
anim
assay
individu
compar
individu
preimmun
titer
ammonium
thiocyan
competit
bind
elisacorn
well
micro
titer
plate
coat
purifi
per
well
bicarbon
buffer
nahco
overnight
well
wash
block
superblock
normal
goat
serum
whey
incub
sera
appropri
dilut
determin
earlier
igg
bind
elisa
give
optic
densiti
od
read
optim
dilut
replic
column
plate
incub
room
temperatur
plate
wash
variou
concentr
ammonium
thiocyan
nh
scn
rang
dilut
sodium
phosphat
buffer
nah
po
ad
column
decreas
molar
incub
minut
plate
wash
incub
apconjug
goat
antimous
ig
sigma
wash
bound
serum
igg
detect
ad
pnpp
substrat
phosphat
sigma
direct
manufactur
incub
minut
read
sampl
run
duplic
compar
initi
absorb
od
absenc
nh
scn
sampl
use
simpl
regress
line
absorb
read
presenc
increas
concentr
nh
scn
convert
percentag
initi
absorb
absenc
nh
scn
data
graph
xaxi
repres
molar
concentr
nh
scn
yaxi
repres
percent
initi
absorb
bind
index
estim
molar
concentr
nh
scn
requir
reduc
initi
absorb
comet
reduct
assaycorn
well
tissu
cultur
plate
seed
african
green
monkey
cell
use
dulbecco
modifi
eagl
medium
dmem
contain
heatinactiv
fetal
bovin
serum
fb
penicillin
streptomycin
plate
incub
overnight
co
vaccinia
viru
strain
intern
health
depart
j
ihdj
provid
dr
richard
moyer
univers
florida
sonic
minut
water
bath
dilut
sera
antibiot
free
dmem
yield
plaqu
per
ml
cell
monolay
wash
use
dmem
fb
penstrep
dilut
ihdj
ad
well
incub
absorpt
viru
inoculum
remov
sampl
mous
sera
contain
neutral
antibodi
ad
amount
well
well
well
give
total
sampl
across
plate
separ
dilut
antibodi
sampl
per
well
dmem
fb
contain
penstep
ad
plate
incub
media
remov
monolay
stain
crystal
violet
visual
comet
format
reduct
glycosyl
type
membran
protein
locat
outer
membran
extracellular
envelop
virion
eev
conserv
among
poxvirus
homologu
among
mani
mammalian
orthopoxvirus
includ
variola
vaccinia
ectodomain
encompass
four
domain
resembl
short
consensu
repeat
scr
present
complement
regulatori
protein
plu
amino
acid
stalk
next
transmembran
region
epitop
map
studi
suggest
stalk
interact
first
two
scr
domain
region
import
neutral
site
vector
studi
express
codonoptim
truncat
transmembran
cytoplasm
domain
remov
figur
detail
descript
vaccin
vector
construct
provid
method
section
figur
show
western
blot
express
vaccin
vector
except
msmegmati
msmegmati
express
low
level
protein
could
readili
detect
western
blot
vector
express
robust
level
protein
express
smegmati
bare
detect
western
blot
presenc
gene
confirm
sequenc
determin
whether
vaccin
express
vaccin
vector
could
induc
primari
immun
respons
mice
immun
adult
mice
vector
measur
serum
antibodi
titer
via
bind
elisa
dose
vector
list
method
section
immun
schedul
shown
figur
order
standard
immun
protocol
much
possibl
elect
give
immun
intramuscularli
singl
inject
diluent
steril
salin
thu
prime
vector
studi
variabl
dose
vaccin
vector
dose
vector
base
individu
preliminari
experi
dose
give
optim
immun
respons
determin
dose
rang
test
provid
method
rvsv
vrp
dose
limit
amount
viru
could
deliv
inocul
volum
primari
humor
respons
assay
four
data
shown
six
week
figur
post
immun
bind
elisa
titer
chang
significantli
group
four
six
week
post
immun
vector
induc
detect
serum
antibodi
titer
except
smegmati
antibodi
detect
anim
immun
smegmati
potenti
smegmati
vector
express
inadequ
level
protein
induc
detect
immun
respons
six
immun
group
compar
statist
singl
anova
multipl
comparison
analysi
tukey
induc
significantli
higher
primari
antibodi
titer
vector
test
p
anova
tukey
multipl
comparison
test
recombin
protein
oligocpg
induc
significantli
higher
titer
vector
except
signific
level
signific
differ
titer
induc
rvsv
vrp
vector
titer
induc
dna
significantli
lower
group
test
signific
level
six
week
singl
primari
immun
anim
boost
singl
dose
either
rvsv
boost
vector
chosen
shown
numer
studi
induc
synergist
respons
incorpor
heterolog
primeboost
regimen
addit
cohort
anim
immun
boost
vector
alon
control
serum
collect
two
week
boost
one
two
three
month
post
boost
assay
individu
titer
via
bind
elisa
serum
ab
titer
increas
group
boost
data
group
time
point
shown
tabl
peak
titer
group
indic
shade
figur
show
averag
peak
titer
primeboost
group
individu
anim
peak
titer
determin
independ
time
titer
reach
averag
peak
titer
calcul
group
immun
group
fell
three
tier
base
peak
titer
indic
tabl
simplic
discuss
statist
analys
perform
use
averag
peak
titer
group
overal
rank
primeboost
effect
use
titer
latest
timepoint
month
post
boost
versu
averag
peak
titer
calcul
independ
time
top
group
induc
highest
overal
titer
protein
boost
protein
primevsv
boost
primevsv
boost
optim
prime
boost
regimen
induc
postboost
antibodi
titer
higher
titer
achiev
primari
immun
b
higher
titer
achiev
boost
vector
alon
experi
prime
boost
regimen
except
prime
vsv
boost
anova
satisfi
first
criteria
ie
group
peak
post
boost
titer
significantli
higher
induc
primari
immun
alon
p
anova
tukey
multipl
comparison
test
group
primari
titer
compar
post
boost
titer
singl
primari
immun
induc
averag
peak
titer
compar
titer
result
heterolog
primeboost
regimen
boost
vector
versu
induc
immun
alon
found
boost
regimen
induc
significantli
higher
postboost
titer
protein
boost
student
test
p
indic
prime
protein
significantli
augment
titer
could
achiev
immun
alon
boost
group
test
p
valu
greater
indic
effect
prime
contrast
regimen
rvsv
boost
vector
induc
titer
significantli
primari
respons
rvsv
gmt
group
p
except
msmegvsv
student
test
indic
prime
heterolog
vector
ad
significantli
titer
could
achiev
immun
rvsv
alon
unless
prime
vector
suggest
rvsv
synergist
boost
vector
gener
order
determin
quantit
prime
boost
combin
synergist
defin
synergi
mathemat
synergylog
pb
p
b
pb
post
boost
titer
p
b
titer
induc
prime
boost
vector
alon
post
boost
titer
sum
titer
induc
prime
boost
vector
deliv
singli
definit
would
synergi
estim
valu
synergi
would
zero
synergist
prime
boost
combin
post
boost
titer
increas
rel
primari
respons
prime
boost
vector
consid
separ
calcul
primeboost
group
test
posit
synergi
vrpvsv
dnavsv
proteinvsv
synergist
prime
boost
combin
significantli
level
synergist
primeboost
combin
test
synergi
within
group
differ
among
signific
level
result
present
demonstr
primeboost
regimen
test
gener
high
titer
antibodi
mani
case
vaccin
efficaci
depend
upon
amount
antibodi
gener
upon
strength
bind
immunoglobulin
antigen
determin
whether
avid
antibodi
gener
differ
vaccin
regimen
perform
competit
bind
elisa
absolut
amount
ab
sampl
equal
bind
titer
determin
presenc
increas
molar
quantiti
ammonium
thiocyan
nh
scn
avid
index
defin
amount
nh
scn
necessari
reduc
bind
higher
avid
abag
interact
requir
higher
concentr
nh
scn
disrupt
singl
primari
immun
anim
immun
highest
avid
ab
figur
antibodi
anim
immun
protein
vrp
dna
approxim
equal
avid
much
lower
gener
antibodi
titer
smegmati
immun
anim
low
measur
therefor
sera
anim
includ
analysi
ideal
vaccin
regimen
would
induc
immun
respons
matur
ie
increas
avid
time
determin
vaccin
regimen
fulfil
requir
assay
avid
two
week
figur
c
two
month
figur
e
singl
booster
immun
boost
rais
equal
avid
ab
group
two
week
post
boost
figur
higher
avid
ab
maintain
two
month
timepoint
figur
contrast
vsv
boost
rais
avid
ab
vrp
dna
prime
anim
two
week
boost
two
month
postboost
dnavsv
anim
ab
increas
avid
vrpvsv
immun
anim
never
reach
higher
avid
induc
vrp
prime
alon
one
import
mechan
action
antibodi
abil
neutral
whole
viru
restrict
dissemin
progeni
virion
abil
antipoxviru
antibodi
restrict
viral
spread
assess
via
comet
assay
vaccinia
strain
ihdj
vihdj
mutant
strain
produc
larg
number
eev
particl
mediat
long
rang
dissemin
infect
host
vitro
vihdj
form
characterist
comet
eev
releas
cultur
medium
vihdj
plaqu
assay
perform
presenc
antibodi
capabl
bind
neutral
eev
comet
tail
reduc
elimin
figur
show
result
comet
assay
perform
use
pool
postimmun
sera
mice
vaccin
vector
primari
immun
sera
collect
immun
mice
sampl
neutral
comet
format
figur
left
panel
row
boost
figur
middl
panel
vsv
figur
right
panel
sera
test
neutral
comet
format
use
highest
amount
boost
comet
neutral
activ
present
sampl
even
ab
present
significantli
lower
quantiti
sampl
fail
neutral
primari
immun
show
abil
restrict
viral
dissemin
assay
sole
function
amount
ab
serum
reflect
function
differ
ab
data
present
far
demonstr
immun
vaccin
vector
induc
high
titer
serum
ab
abl
restrict
viral
spread
vitro
assay
determin
whether
result
vitro
correl
function
vivo
challeng
immun
mice
vaccinia
wr
vvwr
sinc
immun
respons
direct
singl
poxviru
antigen
rare
confer
full
protect
lethal
challeng
decid
challeng
anim
subleth
dose
vvwr
subleth
dose
caus
signific
weight
loss
prechalleng
bodi
weight
naiv
control
anim
mortal
mice
immun
intramuscularli
primari
boost
vector
three
month
boost
challeng
intranas
pfu
vvwr
figur
show
averag
preinfect
bodi
weight
figur
vsv
figur
boost
anim
mice
per
group
anim
prime
boost
mva
includ
posit
control
protect
four
day
post
challeng
mock
immun
control
anim
began
lose
weight
show
sign
ill
ten
day
post
challeng
eight
twelv
mock
immun
control
anim
die
sacrif
accord
anim
protocol
mortal
anim
boost
surviv
regardless
primari
immun
among
vsv
boost
anim
three
anim
die
one
dna
prime
group
two
smegmati
prime
group
vsv
boost
group
show
overal
greater
patholog
challeng
sever
prolong
weight
loss
patholog
correl
group
individu
anim
level
serum
ab
titer
prechalleng
anim
higher
titer
show
less
patholog
challeng
determin
whether
intramuscular
immun
singl
dose
either
boost
vector
enough
confer
protect
challeng
immun
separ
cohort
anim
either
mice
per
group
describ
figur
three
month
singl
immun
anim
challeng
subleth
dose
vvwr
figur
b
figur
show
averag
preinfect
bodi
weight
group
challeng
anim
immun
singl
dose
lost
littl
weight
show
minim
sign
ill
contrast
mock
immun
immun
anim
lost
weight
rapidli
day
show
sign
clinic
ill
respiratori
distress
immun
anim
surviv
eight
fifteen
rvsv
immun
anim
surviv
four
ten
surviv
mock
immun
anim
surviv
differ
surviv
rate
rvsv
mock
immun
anim
statist
signific
mantelcox
logrank
test
data
demonstr
singl
immun
rvsv
suffici
confer
protect
patholog
caus
subleth
challeng
vvwr
one
challeng
vaccin
use
needl
vaccin
deliveri
determin
whether
vaccin
immunogen
deliv
needlefre
rout
test
immunogen
three
vector
given
intranas
sinc
larg
bodi
preexist
literatur
describ
deliveri
protein
vaccin
via
intranas
rout
chose
investig
prime
boost
combin
three
immunogen
vector
vsv
vrp
determin
whether
intranas
vaccin
express
vaccin
vector
could
induc
primari
immun
respons
compar
induc
intramuscular
immun
mice
immun
adult
mice
vector
measur
serum
antibodi
titer
via
bind
elisa
dose
vector
intramuscular
experi
volum
intranas
inocula
per
mous
six
week
primari
immun
three
vaccin
group
significantli
higher
titer
p
vrp
vsv
anova
gener
intramuscular
immun
figur
intranas
deliveri
vsv
vrp
increas
titer
gener
intramuscular
deliveri
gener
titer
increas
heterolog
boost
anim
show
greatli
increas
serum
ab
titer
primedvrp
boost
anim
highest
overal
titer
figur
gener
titer
gener
intranas
primeboost
much
higher
gener
intramuscular
immun
group
averag
peak
endpoint
titer
least
data
demonstr
vsv
vrp
vector
immunogen
deliv
intranas
suggest
deliv
vaccin
intranas
may
lead
induct
better
immun
respons
amount
antigen
dose
spare
rel
intramuscular
rout
determin
whether
antibodi
gener
intranas
immun
protect
vivo
challeng
immun
mice
vaccinia
wr
vvwr
figur
intramuscular
immun
experi
mice
challeng
three
month
singl
booster
immun
figur
e
show
averag
preinfect
bodi
weight
intranas
vaccin
anim
four
day
post
challeng
mock
immun
control
anim
began
lose
weight
show
sign
ill
ten
day
post
challeng
eight
ten
mock
immun
control
anim
die
mortal
none
vaccin
per
group
mice
die
statist
signific
differ
amount
weight
lost
differ
group
anova
although
three
six
prime
group
test
show
essenti
patholog
challeng
vrpvsv
vsvvrp
three
group
averag
percent
initi
bodi
weight
never
fell
figur
contrast
intramuscularli
immun
anim
best
protect
group
still
declin
suggest
intranas
immun
better
rout
vaccin
regimen
studi
test
six
vaccin
vector
determin
immunogen
protect
test
dose
b
appropri
develop
vaccin
emerg
biothreat
vaccin
antigen
cpxv
vector
rout
immun
volum
inoculum
vaccin
vector
intrins
differ
dose
could
measur
unit
vector
chosen
order
maxim
immunogen
also
elect
use
dose
could
feasibl
produc
use
current
vaccin
manufactur
techniqu
recombin
adenoviru
immunogen
six
prime
vector
test
induc
significantli
higher
serum
antibodi
titer
immun
antibodi
induc
higher
avid
induc
vector
antibodi
abl
reduc
spread
vaccinia
eev
vitro
addit
singl
dose
protect
anim
intranas
challeng
vaccinia
viru
find
consist
recent
report
kaufman
et
al
author
report
anim
immun
vector
express
differ
poxviru
imv
eev
ag
protect
mice
lethal
poxviru
challeng
data
show
good
standalon
vector
could
use
situat
develop
humor
respons
short
period
time
necessari
protect
tradit
vaccin
induc
suboptim
respons
exampl
highli
pathogen
humantransmiss
influenza
strain
emerg
singl
dose
immun
vector
express
relev
ha
might
protect
vaccin
individu
despit
fact
vector
highli
immunogen
futur
use
rad
vaccin
vector
human
take
consider
result
recent
merck
hiv
vaccin
trial
trial
human
volunt
preexist
antibodi
vaccin
similar
vector
studi
vulner
hiv
infect
individu
receiv
salin
mechan
infect
enhanc
determin
one
possibl
explan
immun
individu
activ
radspecif
memori
cell
hiv
preferenti
infect
activ
memori
cell
thu
infect
may
potenti
individu
encount
hiv
time
cell
activ
true
vaccin
probabl
safe
use
vaccin
pathogen
preferenti
infect
activ
lymphocyt
nonetheless
light
merck
trial
defin
good
altern
rad
vector
imper
studi
primeboost
combin
rvsv
veevrp
highli
synergist
antibodi
induct
protect
mice
challeng
vaccinia
synergi
rvsv
veevrp
may
due
fact
vector
trigger
multipl
complementari
pathogen
recognit
receptor
vector
effici
infect
dendrit
cell
three
vector
test
rvsv
veevrp
induc
significantli
higher
titer
antibodi
better
protect
deliv
intranas
deliv
intramuscularli
intranas
deliveri
viral
vector
may
result
activ
differ
popul
antigen
present
cell
enhanc
cytokin
respons
differ
amount
antigen
product
rel
intramuscular
immun
futur
experi
focu
determin
precis
mechan
enhanc
protect
intranas
vaccin
whether
intranas
vaccin
enhanc
respons
subset
vaccin
antigen
import
goal
followon
studi
aris
work
identifi
mechan
respons
observ
differ
immunogen
differ
vector
factor
potenti
affect
rel
immunogen
vaccin
vector
includ
number
type
host
cell
target
vector
adjuv
effect
vector
due
capac
vector
activ
tlr
innat
pathway
amount
antigen
produc
vector
amount
replic
vector
vivo
durat
vector
antigen
express
qualiti
helper
cell
respons
induc
vector
like
respons
vector
could
alter
varieti
mean
includ
increas
vaccin
dose
therebi
increas
amount
ag
produc
chang
rout
deliveri
number
type
target
cell
affect
ad
addit
adjuv
known
bind
tlr
viral
vector
vsv
vrp
expect
stimul
similar
innat
pathway
target
similar
number
host
cell
persist
similar
length
time
view
one
import
question
rais
studi
vector
much
immunogen
deliv
intramuscularli
viral
vector
vsv
vrp
one
possibl
differ
replic
compet
influenc
immunogen
rvsv
use
experi
highli
attenu
replic
vivo
vrp
construct
fulli
replic
defici
abil
replic
usual
increas
rather
decreas
immunogen
sinc
vrp
rvsv
vector
administ
similar
dose
pfu
pfu
respect
would
expect
rvsv
vector
induc
higher
titer
vrp
vector
replic
compet
posit
influenc
induct
humor
respons
instead
titer
gener
rvsv
significantli
differ
fact
somewhat
lower
gener
vrp
conclud
absolut
replic
compet
affect
outcom
studi
seem
factor
balanc
contribut
replic
compet
immunogen
interestingli
fulli
vsvg
delet
vector
replic
shown
equal
greater
immunogen
replic
compet
rvsv
express
antigen
thu
unlik
immunogen
vsv
could
enhanc
use
less
attenu
construct
anoth
reason
induc
better
immun
respons
vrp
rvsv
vector
may
administ
higher
dose
vp
vs
pfu
preliminari
doseoptim
studi
higher
dose
uniformli
induc
higher
ab
titer
although
foldincreas
suggest
abl
administ
equal
dose
rvsv
vrp
might
obtain
immun
respons
equal
magnitud
viral
vector
although
qualit
differ
ie
affin
may
remain
consist
deliv
three
viral
vector
intranas
rather
intramuscular
rout
greatli
decreas
dispar
respons
rvsv
vrp
even
though
dose
three
vector
experi
use
intramuscular
trial
demonstr
factor
dose
rout
deliveri
target
organ
profoundli
influenc
immun
respons
gener
vaccin
goal
studi
test
vaccin
vector
might
use
real
vaccin
human
patient
vector
inject
human
dose
pfu
gene
therapi
applic
equival
dose
vrp
highli
attenu
rvsv
vector
formul
administ
safe
like
three
vector
could
use
heterolog
primeboost
combin
induc
robust
humor
respons
varieti
agent
strength
studi
mani
variabl
possibl
held
constant
allow
headtohead
comparison
immunogen
studi
provid
start
point
mechanist
studi
elucid
molecular
interact
give
rise
differ
immunogen
vaccin
vector
vaccin
vector
experi
construct
express
truncat
transmembran
cytoplasm
domain
delet
schemat
draw
cpxv
gene
insert
shown
panel
express
verifi
vaccin
vector
via
western
blot
panel
b
sampl
prepar
appropri
vector
lysat
infect
transfect
cell
resolv
sdspage
attempt
made
equal
protein
load
differ
sampl
ie
dna
vrp
lysat
cell
infect
modifi
vaccinia
ankara
mva
lane
includ
posit
control
express
express
mva
nativ
nontrunc
form
vector
express
truncat
form
adult
femal
mice
immun
singl
intramuscular
inject
express
vaccin
vector
six
week
immun
mice
bled
titer
determin
bind
elisa
n
mice
per
group
dna
protein
vrp
smegmati
mice
per
group
rvsv
mock
immun
sera
assay
individu
endpoint
titer
defin
dilut
read
background
background
read
preimmun
sera
individu
anim
bar
graph
geometr
mean
titer
immun
group
error
bar
repres
upper
lower
limit
confid
interv
data
shown
compil
two
duplic
experi
adult
femal
mice
immun
singl
intramuscular
inject
express
vaccin
vector
indic
tabl
six
week
primari
immun
mice
boost
singl
booster
immun
either
open
bar
shade
bar
anim
bled
multipl
timepoint
boost
two
week
three
month
post
boost
sera
assay
individu
bind
activ
endpoint
titer
defin
dilut
read
background
background
read
preimmun
sera
individu
anim
bar
graph
peak
geometr
mean
titer
immun
group
error
bar
repres
upper
lower
limit
confid
interv
peak
titer
highest
titer
reach
individu
anim
regardless
time
titer
reach
group
contain
anim
individu
sera
mice
immun
intramuscularli
vector
assay
avid
via
competit
bind
elisa
graph
show
bind
curv
sera
collect
six
week
primari
immun
panel
two
week
singl
booster
immun
panel
b
c
two
month
boost
panel
e
calcul
averag
avid
index
group
indic
graph
legend
avid
index
defin
concentr
nh
scn
requir
reduc
bind
individu
sampl
sampl
assay
quadrupl
data
shown
first
largescal
immun
experi
least
mice
per
group
prior
boost
mice
per
group
boost
avid
indic
also
calcul
sampl
collect
second
experi
ident
shown
pool
sera
mice
immun
intramuscularli
vector
assay
abil
inhibit
comet
format
vaccinia
ihdj
figur
show
repres
plaqu
assay
group
pool
sera
cell
infect
approxim
pfu
vihdj
presenc
indic
postimmun
sera
sera
test
assay
collect
three
month
boost
reduct
format
comet
tail
indic
presenc
neutral
ab
mice
prime
boost
intramuscularli
vector
describ
figur
three
month
singl
booster
immun
anim
challeng
intranas
pfu
vvwr
graph
panel
b
show
averag
percent
initi
immun
control
anim
group
per
group
anim
lose
preinfect
bodi
weight
euthan
accord
anim
protocol
day
challeng
mock
immun
control
anim
dead
determin
whether
immun
boost
vector
alon
could
protect
anim
challeng
immun
separ
cohort
mice
intramuscularli
vp
pfu
three
month
immun
mice
challeng
adult
femal
mice
immun
singl
intranas
inocul
express
vaccin
vector
indic
tabl
six
week
primari
immun
mice
boost
singl
booster
immun
either
dose
boost
prime
anim
bled
primari
panel
booster
panel
b
immun
sera
assay
individu
bind
activ
endpoint
titer
defin
dilut
read
background
background
read
preimmun
sera
individu
anim
bar
graph
peak
geometr
mean
titer
immun
group
per
group
error
bar
repres
upper
lower
limit
confid
interv
three
month
boost
anim
anim
challeng
intranas
pfu
vvwr
graph
panel
ce
show
averag
percent
initi
immun
control
anim
group
per
vaccin
group
plot
shown
experi
shown
three
separ
graph
clariti
day
challeng
mock
immun
control
anim
dead
panel
f
show
maximum
percent
weight
loss
group
challeng
bar
repres
averag
group
differ
maximum
weight
loss
statist
signific
among
immun
group
anova
tabl
boost
heterolog
vector
increas
titer
averag
peak
titer
induc
singl
rvsv
immun
alon
respect
titer
shown
geometr
mean
titer
shade
indic
highest
averag
titer
reach
primeboost
regimen
titer
rank
three
group
high
medium
low
indic
tier
respect
vaccin
author
manuscript
avail
pmc
novemb
